SCHEMBL4965370

SCHEMBL4965370

Fc1ccc(Br)c(CCCl)c1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 1/20 0.34
FFAR1 O14842 1/20 0.33
FFAR4 Q5NUL3 1/20 0.33
PKM P14618 1/20 0.33
HTR2A P28223 1/20 0.32
PSEN1 P49768 1/20 0.32
PSEN2 P49810 1/20 0.32
APH1B Q8WW43 1/20 0.32
NCSTN Q92542 1/20 0.32
APH1A Q96BI3 1/20 0.32
PSENEN Q9NZ42 1/20 0.32
RIPK1 Q13546 1/20 0.31
GRM2 Q14416 1/20 0.31
IDO1 P14902 1/20 0.31
AGXT P21549 1/20 0.31
DAO P14920 1/20 0.30
MEN1 O00255 1/20 0.30
ALDH1A1 P00352 1/20 0.30
POLB P06746 1/20 0.30
MAPT P10636 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11772436 0.83 PKM (0.36) DPP4PKMGRM2IDO1AGXT
SCHEMBL3075261 0.83 DPP4 (0.36) DPP4FFAR1FFAR4PKMHTR2A
SCHEMBL19602322 0.81 DPP4 (0.35) DPP4FFAR1FFAR4PKMHTR2A
SCHEMBL13064232 0.79 F2RL1 (0.40) DPP4HTR2AMAPTNR3C1
SCHEMBL535214 0.79 TAAR1 (0.52) DPP4HTR2AIDO1AGXTMEN1
SCHEMBL485871 0.79 PKM (0.36) DPP4FFAR1FFAR4PKMHTR2A
SCHEMBL17979919 0.79 PKM (0.36) DPP4FFAR1FFAR4PKMHTR2A
SCHEMBL30814757 0.79 TAAR1 (0.52) DPP4HTR2AIDO1AGXTMEN1
SCHEMBL30360615 0.79 PKM (0.36) DPP4FFAR1FFAR4PKMHTR2A
SCHEMBL18908301 0.79 DPP4 (0.34) DPP4FFAR1FFAR4PKMHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080171737-A1 CYCLIC SULFONAMIDE DERIVATIVES AND METHODS OF THEIR USE WYETH (US) 2008-07-17 US disclosed
WO-2008073956-A2 CYCLIC SULFONAMIDE DERIVATIVES AND METHODS OF THEIR USE WYETH (US) 2008-06-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080171737-A1 CYCLIC SULFONAMIDE DERIVATIVES AND METHODS OF THEIR USE SLC6A4, SLC6A2, SLC6A3 DPP4 491/4885FFAR1 1167/4885FFAR4 1285/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.